KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $4.2 billion.

  • Amgen's Free Cash Flow rose 2818.35% to $4.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 billion, marking a year-over-year increase of 8365.43%. This contributed to the annual value of $10.4 billion for FY2024, which is 4124.2% up from last year.
  • Amgen's Free Cash Flow amounted to $4.2 billion in Q3 2025, which was up 2818.35% from $1.9 billion recorded in Q2 2025.
  • In the past 5 years, Amgen's Free Cash Flow ranged from a high of $4.4 billion in Q4 2024 and a low of $289.0 million during Q4 2023
  • For the 5-year period, Amgen's Free Cash Flow averaged around $2.2 billion, with its median value being $2.2 billion (2021).
  • As far as peak fluctuations go, Amgen's Free Cash Flow plummeted by 8748.38% in 2023, and later surged by 142249.13% in 2024.
  • Over the past 5 years, Amgen's Free Cash Flow (Quarter) stood at $2.5 billion in 2021, then fell by 8.41% to $2.3 billion in 2022, then tumbled by 87.48% to $289.0 million in 2023, then skyrocketed by 1422.49% to $4.4 billion in 2024, then dropped by 3.45% to $4.2 billion in 2025.
  • Its last three reported values are $4.2 billion in Q3 2025, $1.9 billion for Q2 2025, and $980.0 million during Q1 2025.